In this issue:
- Venetoclax for nontrial patients with MM
- Teclistamab for relapsed/ refractory MM
- COVID-19 outcomes in MM patients treated with novel drugs
- Venetoclax + carfilzomib-dexamethasone in relapsed/ refractory MM
- Lenalidomide maintenance duration and salvage regimen outcomes in MM
- Antimyeloma treatment affects response to COVID-19 vaccines
- Maintenance daratumumab after VTd ±daratumumab and autologous SCT in newly diagnosed MM
- Serum BCMA level predicts time to smouldering MM progression
- Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 for MM
- Predicting survival and optimising treatment in MM using machine learning
Please login below to download this issue (PDF)